|
|
Edinburgh Research Archive >
Molecular, Genetic and Population Health Sciences, School of >
Molecular, Genetic and Population Health Sciences publications >
Please use this identifier to cite or link to this item:
http://hdl.handle.net/1842/4590
|
| Title: | Antithrombotic drug use, cerebral microbleeds and intracerebral haemorrhage: a systematic review of published and unpublished studies |
| Authors: | Lovelock, CE Cordonnier, C Naka, H Al-Shahi Salman, R Sudlow, Cathie Sorimachi, T Werring, DJ Gregoire, SM Imaizumi, T Lee, SH Briley, D Jackson, Caroline Anne Dennis, M Wardlaw, Joanna M Potter, Gillian Margaret Rothwell, PM |
| Issue Date: | Jun-2010 |
| Journal Title: | Stroke |
| Volume: | 41 |
| Issue: | 6 |
| Page Numbers: | 1222-1228 |
| Publisher: | American Heart Association |
| Abstract: | Background and Purpose— Cerebral microbleeds (MB) are potential risk factors for intracerebral hemorrhage (ICH), but it is unclear if they are a contraindication to using antithrombotic drugs. Insights could be gained by pooling data on MB frequency stratified by antithrombotic use in cohorts with ICH and ischemic stroke (IS)/transient ischemic attack (TIA).
Methods— We performed a systematic review of published and unpublished data from cohorts with stroke or TIA to compare the presence of MB in: (1) antithrombotic users vs nonantithrombotic users with ICH; (2) antithrombotic users vs nonusers with IS/TIA; and (3) ICH vs ischemic events stratified by antithrombotic use. We also analyzed published and unpublished follow-up data to determine the risk of ICH in antithrombotic users with MB.
Results— In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3–3.5) in nonantithrombotic users to 5.7 (range, 3.4–9.7) in antiplatelet users and 8.0 (range, 3.5–17.8) in warfarin users (P difference=0.01). There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6–4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9–1.7; P=0.33; P difference=0.01). There was a smaller excess of MB in antiplatelet users vs nonusers with ICH (OR, 1.7; 95% CI, 1.3–2.3; P<0.001), but findings were similar for antiplatelet users with IS/TIA (OR, 1.4; 95% CI, 1.2–1.7; P<0.001; P difference=0.25). In pooled follow-up data for 768 antithrombotic users, presence of MB at baseline was associated with a substantially increased risk of subsequent ICH (OR, 12.1; 95% CI, 3.4–42.5; P<0.001).
Conclusions— The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated ICH. Limited prospective data corroborate these findings, but larger prospective studies are urgently required. |
| Keywords: | warfarin stroke microbleeds intracerebral hemorrhage antiplatelet agents |
| URI: | http://stroke.ahajournals.org/cgi/content/abstract/41/6/1222 http://hdl.handle.net/1842/4590 |
| ISSN: | 0039-2499 |
| Appears in Collections: | Molecular, Genetic and Population Health Sciences publications
|
Items in ERA are protected by copyright, with all rights reserved, unless otherwise indicated.
|